Please be aware that all clinical studies at TUCC are voluntary, meaning that patients may drop out of the study at any time. All study procedures and medication will be provided to patients free of charge.
Click on a study below to review its description:
- Benign Prostatic Hyperplasia (BPH)
TUCC is currently enrolling men in a Phase III study evaluating NX-1207 for the treatment of benign prostatic hyperplasia (BPH). This study incorporates a different delivery administration of a new drug.
Call 303.421.5783 to learn more about this study.
- Bladder Cancer
TUCC is currently enrolling patients in three different clinical trials for the treatment of bladder cancer.
- A maintenance study evaluating the effectiveness and safety with EN3348 vs. Mitomycin C in individuals with non-muscle invasive cancer who are also BCG recurrent or refractory. Patient inclusion criteria: BCG recurrent or refractory. High grade bladder cancer with or without Carcinoma in situ of bladder or Carcinoma in Situ with or without Ta or T1. No evidence of urothelial carcinoma involving upper urinary tract or the urethra.
- A Phase III, double blind, placebo-controlled, randomized trial evaluating the efficacy and safety of multiple instillations of intravesical therapy vs. placebo in patients with low-intermediate risk of non-muscle invasive bladder cancer. Patients who been scheduled for a TURBT may receive a prophylactic dose and possibly multiple instillations of an approved medication which may prevent recurrences. Patient inclusion criteria: Primary or recurrent low to high grade tumors.
- A Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma. This study incorporates a novel immunotherapy given intravenously.
Please call 303.421.5783 to learn more about these studies.
- Prostate Cancer
TUCC is currently enrolling patients in five different clinical trials for the treatment of prostate cancer.
- A Phase II study of Abiraterone Acetate plus Prednisone in subjects with advanced prostate cancer without radiographic evidence of metastatic disease. This approved medication will be studied to possibly offset the progression of non-metastatic prostate cancer in patients currently on hormonal therapy with a rising PSA.
- A Phase II study of Sipuleucel-T with concurrent vs. sequential administration of Abiraterone Acetate plus Prednisone in men with metastatic castrate resistant prostate cancer. Patients must have progression of mestastatic disease by either rising PSA or bone/soft tissue disease.
- A Phase II efficacy and safety study of MDV3100 vs. Bicalutamide in castrate men with metastatic prostate cancer.
- Study to evaluate new or worsening lens opacifications in subjects with nonmetastatic prostate cancer receiving Denosumab for bone loss due to androgen deprivation therapy. This is a clinical trial that incorporates an approved bone loss prevention medication.
- A Phase II, open label trial studying the sequencing of Sip-T and androgen deprivation therapy in patients with non-metastatic prostate cancer. These men will receive a novel immunotherapy after a radical prostatectomy or radiation therapy. Patient exclusion/inclusion criteria: Rising PSA after primary therapy of radical prostatectomy or radiation therapy. Cannot have more than six months of previous hormonal therapy.
Please call 303.421.5783 to learn more about these studies.
